Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aprutumab
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Aprutumab (BAY 1179470) is a fully human monoclonal antibody that targets fibroblast growth factor receptor 2 (FGFR2), specifically binding to the FGFR2 isoforms IIIb and IIIc. It was developed as an antineoplastic agent with potential activity against various solid tumors by antagonizing the FGFR2 pathway. Aprutumab was also used as the antibody component in the antibody-drug conjugate aprutumab ixadotin (BAY 1187982), which linked it to an auristatin-based cytotoxic payload for targeted cancer therapy. The drug was developed by Bayer and reached phase I clinical trials for advanced refractory solid tumors but did not progress further due to dose-limiting toxicities observed at subtherapeutic levels[1][3][4][5].
- Other names
- aprutumabBAY 1187982BAY1187982BAY-1187982CAS 1634620-63-5CAS1634620-63-5CAS-1634620-63-5
02
Targets
FGFR2 (Keratinocyte growth factor receptor)
Beyond the preview
Go deeper on aprutumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aprutumab.